Results

C4 Therapeutics Inc.

06/14/2021 | Press release | Distributed by Public on 06/14/2021 12:11

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT7455, An Orally Bioavailable MonoDAC for Hematologic Malignancies